UZ-UCSF CTU

乌兹别克斯坦大学旧金山分校 CTU

基本信息

批准号：
8969658
负责人：
ZVAVAHERA MIKE CHIRENJE
金额：
$ 260.26万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-03-01 至 2020-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8969658
关键词：
AIDS clinical trial group AIDS prevention AIDS/HIV problem Acquired Immunodeficiency Syndrome Address Adult Area California Caring Centers of Research Excellence Child Childhood Clinical Clinical Trials Clinical Trials Unit Collaborations Communities Comorbidity Complement Data Enrollment Environment Epidemiology Funding Future Geographic Locations Grant HIV HIV Infections HIV therapy Health Sciences Hepatitis Human Resources IMPAACT Incidence Infection Institution International Laboratories Leadership Mission National Institute of Allergy and Infectious Disease Pathogenesis Persons Pharmacy facility Policies Policy Maker Population Populations at Risk Positioning Attribute Prevalence Prevention Prevention Research Prevention strategy Protocols documentation Research Research Personnel San Francisco Science Site Structure Therapeutic Therapeutic Human Experimentation Training Translating Tuberculosis United States National Institutes of Health Universities Vertical Disease Transmission Zimbabwe authority clinical research site college evidence base experience microbicide outreach prevent programs screening

项目摘要

DESCRIPTION (provided by applicant): The University of Zimbabwe-University of California, San Francisco Collaborative Research Programme (UZUCSF), in collaboration with the University of California, San Francisco (UCSF), is the site of a well-established, large Clinical Trials Unit (CTU) with 4 Clinical Research Sites (CRSs), covering 6 distinct geographic locations within and surrounding Harare, Zimbabwe. Experience gained from leadership and participation in 4 Division of AIDS (DAIDS) Networks (HPTN, MTN, ACTG, IMPAACT), positions the CTU to continue its contribution to the global understanding of HIV epidemiology and pathogenesis by serving as a center of research excellence in the prevention and control of HIV and AIDS. Utilizing the expertise of our international and local complement of investigators and highly trained and experienced research personnel, the CTU will accomplish this through completion of the following Specific Aims: 1.a. Identifying, screening, enrolling, and retaining existing and new at-risk populations in an environment of declining prevalence and incidence, in the following mission-specific domains of scientific priority of the 4 future NIAID-sponsored Networks: i) Adult HIV Therapeutic Strategies, including HIV cure, noninfectious comorbidities, and the infectious co-morbidities of hepatitis and tuberculosis; ii) Strategies to Address HIV and HIV-associated Infections in Pediatric and Maternal Populations; iii) Integrated HIV Prevention Strategies; and iv) Microbicide Strategies to Prevent HIV infections, and 1.b. Contributing to the scientific leadership of the 4 future NIAID-sponsored Networks. 2. Utilizing an increasingly efficient and sophisticated centralized administrative structure to support the uninterrupted execution of protocols across 4 restructured CRSs, laboratory, and pharmacy components. 3. Leveraging the integral relationships developed with the CTU's community partners and diverse stakeholders to disseminate research findings and translate research results into evidence-based best practices and policies at the local, regional, and international levels. RELEVANCE: The CTU's implementation of protocols across the 4 Networks may produce results that translate to policies within Zimbabwe and internationally to reduce HIV incidence and prevalence. The CTU anticipates that this new evidence will further inform policies to reduce the Zimbabwean HIV incidence from its current 3% to 2%; reduce current HIV prevalence from 13% to 7.5%; reduce HIV vertical transmission from the current 14% to <5%; and reduce TB incidence from 633 per 100,000 persons to 200 per 100,000.

描述（由申请人提供）：加利福尼亚津巴布韦大学，旧金山，旧金山合作研究计划（UZUCSF）与加利福尼亚大学旧金山大学（UCSF）合作，是一个建立了良好的临床研究站点（CTU）（CTU）（CTU）（CRSS）（CRSS），覆盖6个不同的临床试验单元（CRSS），覆盖6个不同的临床试验单位（CRSS）津巴布韦。从领导力和参与4分部（HPTN，MTN，ACTG，Impaact）参与的经验中获得的经验使CTU定位，继续其对全球对艾滋病毒流行病学和发病机理的理解的贡献，通过在HIV和HIV和艾滋病的预防和控制方面成为研究的中心。利用我们的国际和本地调查人员的专业知识以及受过培训和经验丰富的研究人员的专业知识，CTU将通过完成以下具体目标来实现这一目标：1.A。识别，筛选，注册和保留现有和新的在患病率和发病率下降的环境中，处于危险的环境中，在以下特定任务的特定领域，这是4种未来NIAID赞助的网络的科学优先级：i）成人艾滋病毒治疗策略，包括HIV治疗，包括非传染性合并症，非感染性，，无感染性，以及肝炎和结核病的感染性合并症； ii）解决艾滋病毒的策略和小儿和母亲种群中与HIV相关的感染； iii）综合艾滋病毒预防策略； iv）防止艾滋病毒感染的微生物策略，1.b。促进了4个未来NIAID赞助的网络的科学领导。 2。利用越来越高效且复杂的集中式行政结构来支持4个重组的CRS，实验室和药房组件中协议的不间断执行。 3。利用与CTU的社区合作伙伴以及各种利益相关者建立的整体关系，以传播研究结果，并将研究结果转化为基于证据的最佳实践和政策，并在当地，地区和国际层面上。相关性：CTU在4个网络中实施协议可能会产生结果，这些结果转化为津巴布韦和国际内部的政策，以降低HIV的发病率和流行。 CTU预计，这一新证据将进一步告知政策，以将津巴布韦HIV发病率从目前的3％降低到2％；将当前的HIV患病率从13％降低到7.5％；将HIV垂直传播从当前的14％降低到<5％；并将结核病的发病率从每10万人的633人减少到每100,000人的200人。